FREE Daily Stock Alerts From Stock-PR.com
National Health Partners, Inc. (OTC:NHPR)
CARExpress is one of the largest networks of hospitals, doctors, dentists, pharmacists and other healthcare providers in the country and is comprised of over 1,000,000 medical professionals that belong to such PPOs as CareMark and Aetna. National Health Partners, Inc primary target customer group is the 47 million Americans who have no health insurance of any kind. The company's secondary target customer group includes the millions of Americans who lack complete health insurance coverage.
National Health Partners, Inc., a leading provider of discount healthcare membership programs, announced the recent signing of two new significant marketing agreements. These two clients provide very different opportunities and continue to expand the reach of CARExpress into new marketplaces.
By launching their own unique internet marketing program, the first group should be able to provide a widespread push into the on-line market to produce an excellent volume of new CARExpress sales into the pipeline. In addition, the second group offers a reach into the wholesale marketplace where CARExpress will be wrapped into other programs to enhance the value of the overall package to the consumer. We would consider this non-traditional business and a great opportunity to expand our reach as well as recognition of the CARExpress program nationwide.
The company plans to announce the rollout of these new marketing campaigns as well as several others over the next few weeks.
National Health Partners, Inc. is a national healthcare savings organization that provides discount healthcare membership programs to uninsured and underinsured people through a national healthcare savings network called "CARExpress."
CARExpress is an affordable membership program which offers significant savings to all members. CARExpress is not insurance! In many ways, it is the perfect complement to insurance since CARExpress offers savings on many products and services that are not included under insurance program. Design your own benefits package to meet your specific needs.
For more information about National Health Partners, Inc. visit its website at www.nationalhealthpartners.com
Crown Equity Holdings Inc. (OTCPK:CRWE)
Crown Equity Holdings Inc., together with its digital network, currently provides electronic media services specializing in online publishing, which brings together targeted audiences and advertisers. Crown Equity Holdings Inc. offers internet media-driven advertising services, which covers and connects a range of marketing specialties, as well as search engine optimization for clients interested in online media awareness.
Crown Equity Holdings Inc. announced that it has extended its CRWENEWSWIRE global platform web presence and is now publishing online news and information to the following countries: Argentina, Australia, Brazil, Canada, China, France, Germany, India, Ireland, Italy, Japan, Malaysia, Mexico, New Zealand, Russia, Singapore, South Africa, South Korea, Spain, Taiwan, United Arab Emirates and the United Kingdom, using their specific country code domain and native language.
Marketing online allows you to track real-time results using online analytics to make a determination on how your marketing campaign is performing. Internet marketing is also quick and lighting fast. Internet marketing services are also considered to be reliable because it allows you to determine how, when, and where your prospects will view your product or service. Internet marketing is a cheap, reliable, quick, and highly effective online marketing medium.
CRWE's selection of CoreLink reflects recent diversification beyond CRWE's original charter as a provider of services and knowledge to small business owners taking their own companies public. In addition to these services, CRWE has transitioned into a multifaceted media organization that publishes clients' news online; sells advertising adjacent with its digital network targeted at a high-income audience; designs, hosts and maintains websites; produces marketing videos from concept to final product; crafts press releases and articles for maximum SEO; develops email campaigns; and forges branding campaigns to bolster client company images.
Please Visit Crown Equity Holdings Inc. website http://www.crownequityholdings.com
ViroPharma Incorporated (Nasdaq:VPHM) announced that the European Commission has granted ViroPharma Centralized Marketing Authorization for CinryzeÂ® (C1 inhibitor [human]) in adults and adolescents with hereditary angioedema (NYSE:HAE) for routine prevention, pre-procedure prevention and acute treatment of angioedema attacks. The approval also includes a self administration option for appropriately trained patients included in the Summary of Product Characteristics (SPC).
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options, including C1 esterase inhibitor deficiency, pediatric epilepsy and C. difficile infection (NYSE:CDI). For more information www.viropharma.com.
Alkermes, Inc. (NASDAQ:ALKS) announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and buprenorphine. TRD, which is also known as refractory depression, refers to depressive episodes that are not adequately controlled by standard antidepressant therapy. The multicenter, randomized, double-blind, placebo-controlled trial is designed to assess the safety and potential efficacy of ALKS 5461 in subjects with TRD. Alkermes expects to provide topline results from this study in the second half of calendar 2011.
Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROLÂ® for alcohol and opioid dependence and manufactures RISPERDALÂ® CONSTAÂ® for schizophrenia and bipolar I disorder. For more information, please visit Alkermes' website at www.alkermes.com.
KMG Chemicals, Inc. (NASDAQ:KMGB), a global provider of specialty chemicals in carefully focused markets, announced financial results for its fiscal third quarter ended April 30, 2011. For the third quarter, net sales increased 26% to $65.1 million from $51.6 million in the third quarter of 2010, driven primarily by the inclusion of the Electronic Chemicals business acquired in March 2010 and, to a lesser extent, higher sales of Creosote in the Wood Treating Chemicals business. Operating income in the fiscal 2011 third quarter declined to $4.6 million from $5.8 million in the third quarter of last year. KMG recorded net income of $2.6 million, or $0.23 per diluted share, for the third quarter of fiscal 2011, compared to net income of $3.3 million, or $0.29 per diluted share, in the third quarter of last year.
KMG Chemicals, Inc., through its subsidiaries, engages in the manufacture and sale of specialty chemicals principally in the United States and internationally. It offers high purity wet process chemicals that are used to clean and etch silicon wafers in the production of semiconductors.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) has received 3,000,000 shares of (144) restricted common stock from the company and 3,000,000 shares of free trading shares from a third party (PIERRE BESUCHET) for six months of advertisement services for National Health Partners Inc. (OTC:NHPR).
Sign Up For Free Stock Alerts At http://stock-pr.com/signup